How basal are triple-negative breast cancers?, International Journal of Cancer, vol.9, issue.1, pp.236-240, 2008. ,
DOI : 10.1002/ijc.23518
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes, Clinical Cancer Research, vol.15, issue.7, pp.2302-2310, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2132
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5367-5374, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0220
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.26, issue.8, pp.1275-1281, 2008. ,
DOI : 10.1200/JCO.2007.14.4147
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1145-1153, 2010. ,
DOI : 10.1200/JCO.2009.22.4725
Directed Therapy of Subtypes of Triple-Negative Breast Cancer, The Oncologist, vol.16, issue.Supplement 1, pp.71-78, 2011. ,
DOI : 10.1634/theoncologist.2011-S1-71
Triple-Negative Breast Cancer, New England Journal of Medicine, vol.363, issue.20, pp.1938-1948, 2010. ,
DOI : 10.1056/NEJMra1001389
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer, CancerSpectrum Knowledge Environment, vol.95, issue.19, pp.1482-1485, 2003. ,
DOI : 10.1093/jnci/djg050
Targeted therapies for breast cancer, Journal of Clinical Investigation, vol.121, issue.10, pp.3797-3803, 2011. ,
DOI : 10.1172/JCI57152
What is triple-negative breast cancer?, European Journal of Cancer, vol.44, issue.18, pp.2799-2805, 2008. ,
DOI : 10.1016/j.ejca.2008.09.034
Opinion: Hallmarks of 'BRCAness' in sporadic cancers, Nature Reviews Cancer, vol.56, issue.10, pp.814-819, 2004. ,
DOI : 10.1093/jnci/90.15.1138
Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.103, issue.2, pp.211-225, 2000. ,
DOI : 10.1016/S0092-8674(00)00114-8
URL : https://doi.org/10.1016/s0092-8674(00)00114-8
EGFR and cancer prognosis, European Journal of Cancer, vol.37, issue.4, pp.9-15, 2001. ,
DOI : 10.1016/S0959-8049(01)00231-3
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes, Cancer, vol.350, issue.5, pp.1234-1242, 2010. ,
DOI : 10.1002/cncr.24816
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, vol.7, pp.2958-2970, 2001. ,
Mutation Status, Journal of Clinical Oncology, vol.29, issue.15, pp.2011-2019, 2011. ,
DOI : 10.1200/JCO.2010.33.5091
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-4705, 2010. ,
DOI : 10.1200/JCO.2009.27.4860
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non???Small-Cell Lung Cancer in Asia (IPASS), Journal of Clinical Oncology, vol.29, issue.21, pp.2866-2874, 2011. ,
DOI : 10.1200/JCO.2010.33.4235
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer, Journal of Clinical Oncology, vol.23, issue.23, pp.5323-5333, 2005. ,
DOI : 10.1200/JCO.2005.08.326
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.30, issue.21, pp.2615-2623, 2012. ,
DOI : 10.1200/JCO.2010.34.5579
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer, Annals of Oncology, vol.20, issue.5, pp.862-867, 2009. ,
DOI : 10.1093/annonc/mdn710
Randomized Phase II Study of the Anti???Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.31, issue.20, pp.2586-2592, 2013. ,
DOI : 10.1200/JCO.2012.46.2408
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact, Annals of Oncology, vol.25, issue.8 ,
DOI : 10.1093/annonc/mdu183
Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicentre neoadjuvant pilot phase II study, ASCO Meeting Abstracts, vol.31, p.1057, 2013. ,
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR), Cancer Research, vol.64, issue.15, pp.5355-5362, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0562
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting, Clinical Cancer Research, vol.10, issue.19, pp.6487-6501, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0870
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR, Proceedings of the National Academy of Sciences, vol.311, issue.1-2, pp.1815-1820, 2013. ,
DOI : 10.1016/j.jim.2006.01.018
Epidermal growth factor receptor: mechanisms of activation and signalling, Experimental Cell Research, vol.284, issue.1, pp.31-53, 2003. ,
DOI : 10.1016/S0014-4827(02)00098-8
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, Molecular Cancer Therapeutics, vol.4, issue.4, pp.641-649, 2005. ,
DOI : 10.1158/1535-7163.MCT-04-0329
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors, Clinical Pharmacokinetics, vol.10, issue.14, pp.371-403, 2011. ,
DOI : 10.1158/1078-0432.CCR-04-0058
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines, Molecular Cancer Research, vol.5, issue.2, pp.195-201, 2007. ,
DOI : 10.1158/1541-7786.MCR-06-0263
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003. ,
DOI : 10.1001/jama.290.16.2149
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.21, issue.12, pp.2237-2246, 2003. ,
DOI : 10.1200/JCO.2003.10.038
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer, Clin Cancer Res, vol.11, pp.795-805, 2005. ,
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1208, 2004. ,
DOI : 10.1200/JCO.2004.10.182
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer, Cancer, vol.66, issue.5, pp.980-988, 2007. ,
DOI : 10.1200/JCO.2005.02.0172
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1810, 2005. ,
DOI : 10.1200/JCO.2005.08.037
Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody, Oncogene, vol.12, pp.1397-1403, 1996. ,
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin., Journal of Clinical Investigation, vol.95, issue.4, pp.1897-1905, 1995. ,
DOI : 10.1172/JCI117871
Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage, Cancer Res, vol.63, pp.1-5, 2003. ,
Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis, Clinical Colorectal Cancer, vol.10, issue.1, pp.63-69, 2011. ,
DOI : 10.3816/CCC.2011.n.009
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies, Cancer Research, vol.67, issue.6, pp.2643-2648, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4158
Autocrine Signaling through Ras Regulates Cell Survival Activity in Human Glioma Cells: Potential Cross-Talk between Ras and the Phosphatidylinositol 3-Kinase-Akt Pathway, Journal of Neuropathology & Experimental Neurology, vol.61, issue.11, pp.975-983, 2002. ,
DOI : 10.1093/jnen/61.11.975
PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab, Cancer Research, vol.68, issue.6, pp.1953-1961, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-5659
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.16, pp.2622-2629, 2009. ,
DOI : 10.1200/JCO.2008.20.2796
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005. ,
DOI : 10.1016/S1470-2045(05)70102-9
Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab, Journal of Clinical Oncology, vol.25, issue.22, pp.3238-3245, 2007. ,
DOI : 10.1200/JCO.2007.11.5956
EGFR expression and gene copy number in triple-negative breast carcinoma, Cancer Genetics and Cytogenetics, vol.203, issue.2, pp.222-229, 2010. ,
DOI : 10.1016/j.cancergencyto.2010.07.118
Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations, British Journal of Cancer, vol.486, issue.4, pp.1045-1052, 2014. ,
DOI : 10.1016/j.clinbiochem.2008.09.099
URL : http://www.nature.com/bjc/journal/v110/n4/pdf/bjc2013794a.pdf
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers, Breast Cancer Research, vol.100, issue.15 Suppl, p.15, 2011. ,
DOI : 10.1093/jnci/djm252
Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants, Cancer Research, vol.66, issue.1, pp.41-45, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-2853
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types, Journal of Clinical Oncology, vol.20, issue.21, pp.4292-4302, 2002. ,
DOI : 10.1200/JCO.2002.03.100
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.8, pp.1263-1284, 2007. ,
DOI : 10.1016/j.bbamcr.2006.10.001
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition, Oncogene, vol.12, issue.22, pp.3227-3239, 2007. ,
DOI : 10.1074/jbc.272.47.29967
URL : https://hal.archives-ouvertes.fr/hal-00319874
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance, Clin Cancer Res, vol.9, pp.1161-1170, 2003. ,
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells, Journal of Cellular and Molecular Medicine, vol.30, issue.5, pp.648-656, 2013. ,
DOI : 10.1200/JCO.2011.38.2010
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity, Molecular Cancer Therapeutics, vol.6, issue.8, pp.2168-2177, 2007. ,
DOI : 10.1158/1535-7163.MCT-06-0514
Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (?Iressa?), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells, Journal of Cellular Physiology, vol.61, issue.1, pp.139-150, 2003. ,
DOI : 10.1002/jcp.10239
The retinoblastoma protein and cell cycle control, Cell, vol.81, issue.3, pp.323-330, 1995. ,
DOI : 10.1016/0092-8674(95)90385-2
URL : https://doi.org/10.1016/0092-8674(95)90385-2
CDKN1C Negatively Regulates RNA Polymerase II C-terminal Domain Phosphorylation in an E2F1-dependent Manner, Journal of Biological Chemistry, vol.17, issue.13, pp.9813-9822, 2010. ,
DOI : 10.3945/jn.109.110320
Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity, Anticancer Res, vol.26, pp.3387-3391, 2006. ,
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004. ,
DOI : 10.1056/NEJMoa033025
URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa033025
U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens, Clinical Cancer Research, vol.14, issue.5, pp.1296-1302, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1354
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer, BMC Cancer, vol.13, issue.2 Pt 1, p.136, 2010. ,
DOI : 10.1158/1078-0432.CCR-06-0267
Ras oncogenes: split personalities, Nature Reviews Molecular Cell Biology, vol.21, issue.7, pp.517-531, 2008. ,
DOI : 10.1172/JCI200418829
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915522/pdf
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women, Breast Cancer Research and Treatment, vol.14, issue.2, pp.385-392, 2014. ,
DOI : 10.1186/bcr3150
The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.464, pp.395-399, 2012. ,
DOI : 10.1038/nature08989
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1., Cancer Discovery, vol.2, issue.5, pp.401-404, 2012. ,
DOI : 10.1158/2159-8290.CD-12-0095
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Journal of Clinical Investigation, vol.121, issue.7, pp.2750-2767, 2011. ,
DOI : 10.1172/JCI45014DS1
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression, Molecular Oncology, vol.66, issue.1, pp.84-96, 2007. ,
DOI : 10.1158/0008-5472.CAN-05-4081
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol.10, issue.6, pp.515-527, 2006. ,
DOI : 10.1016/j.ccr.2006.10.008
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier, Cancer Res, vol.58, pp.3237-3242, 1998. ,
Sulforhodamine B colorimetric assay for cytotoxicity screening, Nature Protocols, vol.129, issue.3, pp.1112-1116, 2006. ,
DOI : 10.1038/nprot.2006.179
Breast cancer cell response to genistein is conditioned by BRCA1 mutations, Biochemical and Biophysical Research Communications, vol.379, issue.3, pp.785-789, 2009. ,
DOI : 10.1016/j.bbrc.2008.12.151
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacological Reviews, vol.58, issue.3, pp.621-681, 2006. ,
DOI : 10.1124/pr.58.3.10
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2???????CT Method, Methods, vol.25, issue.4, pp.402-408, 2001. ,
DOI : 10.1006/meth.2001.1262
Sem: a suitable statistical software adaptated for research in oncology], Bull Cancer, vol.87, pp.715-721, 2000. ,